Furthermore, proglumide exhibits a direct anti-tumor effect by blocking upstream PI3K-AKT-mTOR signaling pathways through antagonism of the CCK-BR perhaps allowing for the use of a lower dose of ICI with fewer immune mediated side effects. The gene discussed is MTOR; the disease is neoplasm.